Boulder, Colorado, USA
June 3, 2021
Front Range Biosciences® ("FRB"), a cannabis and hemp genetics platform company, leveraging next generation breeding technology and R&D, announced today that it will license its proprietary technology for cannabis phytochemical detection and quantification along with genomic marker detection and analysis for commercial use to the Centre for Research in Agricultural Genomics, a Spanish consortium ("CRAG") and IRTA, one of the consortium partners. The agreement builds on an existing partnership between the FRB, CRAG, and IRTA formed in 2019 to develop research tools for the genetic improvement of cannabis plants.
The extended partnership provides FRB the opportunity to establish their expertise as a global leader in cannabis genetics and breeding. Spain was one of the first European countries to decriminalize the personal use and cultivation of cannabis for self-consumption. Although cannabis has not been legalized for medical or recreational use, the country's Ministry of Health has authorized organizations to cultivate, process and test cannabis and hemp plants for medical purposes. Last year, IRTA and CRAG received one of eight licenses to work with medical cannabis from the Spanish Agency of Medicine and Sanitary Products and partnered exclusively with FRB to advance the development of medical cannabis genetics for the global marketplace.
"CRAG is a world class research center, and we are pleased to extend our partnership with them by introducing technologies and services that will transform cannabis medical markets across Europe," said Dr. Jonathan Vaught, Co-founder and CEO of Front Range Biosciences.
"The expanded partnership leverages the technological expertise of FRB and the research capabilities and reach of CRAG to accelerate the adoption of cannabis for therapeutic uses in Spain and across the European Union," said José Luis Riechmann, Director of CRAG. "We are happy to expand our collaboration with such a diverse and innovative company as FRB."
Topics
Species
